Ritodrine - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (1)Enzymes (1)

Targets (1)Enzymes (1)Biointeractions (2)

Identification

Name

Ritodrine

Accession Number

DB00867 (APRD00541)

Type

Small Molecule

Groups

Approved

Description

Adrenergic beta-agonist used to control premature labor. [PubChem]

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

DU-21220

Ritodrina

Ritodrine

Ritodrinium

Yutopar

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Ritodrine Hydrochloride	ESJ56Q60GC	23239-51-2	IDLSITKDRVDKRV-UHFFFAOYNA-N	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Yutopar Inj 50mg/5ml	Liquid	10 mg	Intravenous	Bristol Labs Division Of Bristol Myers Squibb	1984-12-31	2001-07-30	Canada
Yutopar Tab 10mg	Tablet	10 mg	Oral	Bristol Labs Division Of Bristol Myers Squibb	1984-12-31	2001-07-30	Canada

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Yutopar	Not Available

Brand mixtures

Not Available

Categories

UNII

I0Q6O6740J

CAS number

26652-09-5

Weight

Average: 287.3535
Monoisotopic: 287.152143543

Chemical Formula

C₁₇H₂₁NO₃

InChI Key

IOVGROKTTNBUGK-SJCJKPOMSA-N

InChI

InChI=1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1

IUPAC Name

4-(2-{[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)phenol

SMILES

C[[email protected]](NCCC1=CC=C(O)C=C1)[[email protected]](O)C1=CC=C(O)C=C1

Pharmacology

Indication

For the treatment and prophylaxis of premature labour

Structured Indications

Not Available

Pharmacodynamics

Beta-2 adrenergic receptors are located at sympathetic neuroeffector junctions of many organs, including uterus. Ritodrine is beta-2 adrenergic agonist. It stimulates beta-2 adrenergic receptor, increases cAMP level and decreases intracellular calcium concentration. The decrease of calcium concentration leads to a relaxation of uterine smooth muscle and, therefore, a decrease in premature uterine contractions.

Mechanism of action

Ritodrine is beta-2 adrenergic agonist. It binds to beta-2 adrenergic receptors on outer membrane of myometrial cell, activates adenyl cyclase to increase the level of cAMP which decreases intracellular calcium and leads to a decrease of uterine contractions.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Beta-2 adrenergic receptor	Protein	yes	agonist	Human	P07550	details

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

~56%

Metabolism

Hepatic, by both the mother and fetus

Route of elimination

Not Available

Half life

1.7-2.6 hours

Clearance

Not Available

Toxicity

LD₅₀=64mg/kg (mice, IV); LD₅₀=540 mg/kg (mice, oral); LD₅₀=85 mg/kg (rat, IV)

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	The risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Ritodrine.	Experimental
Acebutolol	Acebutolol may decrease the bronchodilatory activities of Ritodrine.	Approved
Alfuzosin	Alfuzosin may decrease the vasoconstricting activities of Ritodrine.	Approved, Investigational
Alprenolol	Alprenolol may decrease the bronchodilatory activities of Ritodrine.	Approved, Withdrawn
Amineptine	The risk or severity of adverse effects can be increased when Amineptine is combined with Ritodrine.	Illicit, Withdrawn
Amitriptyline	The risk or severity of adverse effects can be increased when Amitriptyline is combined with Ritodrine.	Approved
Amphetamine	The risk or severity of adverse effects can be increased when Amphetamine is combined with Ritodrine.	Approved, Illicit
Atenolol	Atenolol may decrease the bronchodilatory activities of Ritodrine.	Approved
Atomoxetine	Atomoxetine may increase the hypertensive activities of Ritodrine.	Approved
Bendroflumethiazide	Ritodrine may increase the hypokalemic activities of Bendroflumethiazide.	Approved
Benmoxin	The risk or severity of adverse effects can be increased when Benmoxin is combined with Ritodrine.	Withdrawn
Benzphetamine	The risk or severity of adverse effects can be increased when Benzphetamine is combined with Ritodrine.	Approved, Illicit
Benzylpenicilloyl Polylysine	Ritodrine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.	Approved
Betahistine	The therapeutic efficacy of Ritodrine can be decreased when used in combination with Betahistine.	Approved
Betaxolol	Betaxolol may decrease the bronchodilatory activities of Ritodrine.	Approved
Bisoprolol	Bisoprolol may decrease the bronchodilatory activities of Ritodrine.	Approved
Bopindolol	Bopindolol may decrease the bronchodilatory activities of Ritodrine.	Approved
Bromocriptine	Bromocriptine may increase the hypertensive activities of Ritodrine.	Approved, Investigational
Bucindolol	The risk or severity of adverse effects can be increased when Ritodrine is combined with Bucindolol.	Investigational
Bumetanide	Ritodrine may increase the hypokalemic activities of Bumetanide.	Approved
Bupranolol	Bupranolol may decrease the bronchodilatory activities of Ritodrine.	Approved
Cabergoline	Cabergoline may increase the hypertensive activities of Ritodrine.	Approved
Caroxazone	The risk or severity of adverse effects can be increased when Caroxazone is combined with Ritodrine.	Withdrawn
Carteolol	Carteolol may decrease the bronchodilatory activities of Ritodrine.	Approved
Carvedilol	Carvedilol may decrease the vasoconstricting activities of Ritodrine.	Approved, Investigational
Celiprolol	Celiprolol may decrease the bronchodilatory activities of Ritodrine.	Approved, Investigational
Chlorothiazide	Ritodrine may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Chlorphentermine	The risk or severity of adverse effects can be increased when Ritodrine is combined with Chlorphentermine.	Illicit, Withdrawn
Chlorthalidone	Ritodrine may increase the hypokalemic activities of Chlorthalidone.	Approved
Clenbuterol	The risk or severity of adverse effects can be increased when Ritodrine is combined with Clenbuterol.	Approved, Vet Approved
Clomipramine	The risk or severity of adverse effects can be increased when Clomipramine is combined with Ritodrine.	Approved, Vet Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ritodrine.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Desipramine is combined with Ritodrine.	Approved
Desvenlafaxine	Desvenlafaxine may increase the tachycardic activities of Ritodrine.	Approved
Dihydroergotamine	Dihydroergotamine may increase the hypertensive activities of Ritodrine.	Approved
Dobutamine	The risk or severity of adverse effects can be increased when Dobutamine is combined with Ritodrine.	Approved
Dopamine	The risk or severity of adverse effects can be increased when Ritodrine is combined with Dopamine.	Approved
Dosulepin	The risk or severity of adverse effects can be increased when Dosulepin is combined with Ritodrine.	Approved
Doxazosin	Doxazosin may decrease the vasoconstricting activities of Ritodrine.	Approved
Doxepin	The risk or severity of adverse effects can be increased when Doxepin is combined with Ritodrine.	Approved
Doxofylline	The risk or severity of adverse effects can be increased when Ritodrine is combined with Doxofylline.	Approved
Dronabinol	Dronabinol may increase the tachycardic activities of Ritodrine.	Approved, Illicit
Duloxetine	Duloxetine may increase the tachycardic activities of Ritodrine.	Approved
Ephedrine	The risk or severity of adverse effects can be increased when Ritodrine is combined with Ephedrine.	Approved
Epinephrine	The risk or severity of adverse effects can be increased when Epinephrine is combined with Ritodrine.	Approved, Vet Approved
Ergoloid mesylate	Ergoloid mesylate may increase the hypertensive activities of Ritodrine.	Approved
Ergonovine	Ergonovine may increase the hypertensive activities of Ritodrine.	Approved
Ergotamine	Ergotamine may increase the hypertensive activities of Ritodrine.	Approved
Esmirtazapine	The risk or severity of adverse effects can be increased when Esmirtazapine is combined with Ritodrine.	Investigational
Esmolol	Esmolol may decrease the bronchodilatory activities of Ritodrine.	Approved
Etacrynic acid	Ritodrine may increase the hypokalemic activities of Etacrynic acid.	Approved
Etilefrine	The risk or severity of adverse effects can be increased when Ritodrine is combined with Etilefrine.	Withdrawn
Fenoterol	The risk or severity of adverse effects can be increased when Ritodrine is combined with Fenoterol.	Approved
Furazolidone	The risk or severity of adverse effects can be increased when Furazolidone is combined with Ritodrine.	Approved, Vet Approved
Furosemide	Ritodrine may increase the hypokalemic activities of Furosemide.	Approved, Vet Approved
Hydracarbazine	The risk or severity of adverse effects can be increased when Hydracarbazine is combined with Ritodrine.	Experimental
Hydrochlorothiazide	Ritodrine may increase the hypokalemic activities of Hydrochlorothiazide.	Approved, Vet Approved
Hydroflumethiazide	Ritodrine may increase the hypokalemic activities of Hydroflumethiazide.	Approved
Hydroxyamphetamine	The risk or severity of adverse effects can be increased when Ritodrine is combined with Hydroxyamphetamine hydrobromide.	Approved
Imipramine	The risk or severity of adverse effects can be increased when Imipramine is combined with Ritodrine.	Approved
Indapamide	Ritodrine may increase the hypokalemic activities of Indapamide.	Approved
Indoramin	Indoramin may decrease the vasoconstricting activities of Ritodrine.	Withdrawn
Iobenguane	The therapeutic efficacy of Iobenguane can be decreased when used in combination with Ritodrine.	Approved
Iproclozide	The risk or severity of adverse effects can be increased when Iproclozide is combined with Ritodrine.	Withdrawn
Iproniazid	The risk or severity of adverse effects can be increased when Iproniazid is combined with Ritodrine.	Withdrawn
Isocarboxazid	The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ritodrine.	Approved
Isoprenaline	The risk or severity of adverse effects can be increased when Ritodrine is combined with Isoprenaline.	Approved
Isoxsuprine	The risk or severity of adverse effects can be increased when Ritodrine is combined with Isoxsuprine.	Approved, Withdrawn
Labetalol	The risk or severity of adverse effects can be increased when Labetalol is combined with Ritodrine.	Approved
Levomilnacipran	Levomilnacipran may increase the tachycardic activities of Ritodrine.	Approved
Linezolid	Linezolid may increase the hypertensive activities of Ritodrine.	Approved, Investigational
Mebanazine	The risk or severity of adverse effects can be increased when Mebanazine is combined with Ritodrine.	Withdrawn
Mephentermine	The risk or severity of adverse effects can be increased when Ritodrine is combined with Mephentermine.	Approved
Metaraminol	The risk or severity of adverse effects can be increased when Metaraminol is combined with Ritodrine.	Approved, Investigational
Methamphetamine	The risk or severity of adverse effects can be increased when Ritodrine is combined with Methamphetamine.	Approved, Illicit
Methoxamine	The risk or severity of adverse effects can be increased when Methoxamine is combined with Ritodrine.	Approved
Methyclothiazide	Ritodrine may increase the hypokalemic activities of Methyclothiazide.	Approved
Methylene blue	The risk or severity of adverse effects can be increased when Methylene blue is combined with Ritodrine.	Investigational
Metolazone	Ritodrine may increase the hypokalemic activities of Metolazone.	Approved
Metoprolol	Metoprolol may decrease the bronchodilatory activities of Ritodrine.	Approved, Investigational
Midodrine	The risk or severity of adverse effects can be increased when Midodrine is combined with Ritodrine.	Approved
Milnacipran	Milnacipran may increase the tachycardic activities of Ritodrine.	Approved
Minaprine	The risk or severity of adverse effects can be increased when Minaprine is combined with Ritodrine.	Approved
Mirtazapine	The risk or severity of adverse effects can be increased when Mirtazapine is combined with Ritodrine.	Approved
Moclobemide	The risk or severity of adverse effects can be increased when Moclobemide is combined with Ritodrine.	Approved
Nabilone	Nabilone may increase the tachycardic activities of Ritodrine.	Approved, Investigational
Nadolol	Nadolol may decrease the bronchodilatory activities of Ritodrine.	Approved
Nebivolol	Nebivolol may decrease the bronchodilatory activities of Ritodrine.	Approved, Investigational
Nialamide	The risk or severity of adverse effects can be increased when Nialamide is combined with Ritodrine.	Withdrawn
Norepinephrine	The risk or severity of adverse effects can be increased when Norepinephrine is combined with Ritodrine.	Approved
Nortriptyline	The risk or severity of adverse effects can be increased when Nortriptyline is combined with Ritodrine.	Approved
Octamoxin	The risk or severity of adverse effects can be increased when Octamoxin is combined with Ritodrine.	Withdrawn
Opipramol	The risk or severity of adverse effects can be increased when Opipramol is combined with Ritodrine.	Investigational
Orciprenaline	The risk or severity of adverse effects can be increased when Orciprenaline is combined with Ritodrine.	Approved
Oxprenolol	Oxprenolol may decrease the bronchodilatory activities of Ritodrine.	Approved
Oxymetazoline	The risk or severity of adverse effects can be increased when Ritodrine is combined with Oxymetazoline.	Approved
Pargyline	The risk or severity of adverse effects can be increased when Pargyline is combined with Ritodrine.	Approved
Penbutolol	Penbutolol may decrease the bronchodilatory activities of Ritodrine.	Approved, Investigational
Phenelzine	The risk or severity of adverse effects can be increased when Phenelzine is combined with Ritodrine.	Approved
Pheniprazine	The risk or severity of adverse effects can be increased when Pheniprazine is combined with Ritodrine.	Withdrawn
Phenmetrazine	The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Ritodrine.	Approved, Illicit
Phenoxypropazine	The risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Ritodrine.	Withdrawn
Phentermine	The risk or severity of adverse effects can be increased when Phentermine is combined with Ritodrine.	Approved, Illicit
Phenylephrine	The risk or severity of adverse effects can be increased when Phenylephrine is combined with Ritodrine.	Approved
Phenylpropanolamine	The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Ritodrine.	Approved, Vet Approved, Withdrawn
Pindolol	Pindolol may decrease the bronchodilatory activities of Ritodrine.	Approved
Piretanide	Ritodrine may increase the hypokalemic activities of Piretanide.	Experimental
Pirlindole	The risk or severity of adverse effects can be increased when Pirlindole is combined with Ritodrine.	Approved
Pivhydrazine	The risk or severity of adverse effects can be increased when Pivhydrazine is combined with Ritodrine.	Withdrawn
Polythiazide	Ritodrine may increase the hypokalemic activities of Polythiazide.	Approved
Prazosin	Prazosin may decrease the vasoconstricting activities of Ritodrine.	Approved
Procaterol	The risk or severity of adverse effects can be increased when Ritodrine is combined with Procaterol.	Approved
Propranolol	Propranolol may decrease the bronchodilatory activities of Ritodrine.	Approved, Investigational
Protriptyline	The risk or severity of adverse effects can be increased when Protriptyline is combined with Ritodrine.	Approved
Pseudoephedrine	The risk or severity of adverse effects can be increased when Ritodrine is combined with Pseudoephedrine.	Approved
Quinethazone	Ritodrine may increase the hypokalemic activities of Quinethazone.	Approved
Rasagiline	The risk or severity of adverse effects can be increased when Rasagiline is combined with Ritodrine.	Approved
Safrazine	The risk or severity of adverse effects can be increased when Safrazine is combined with Ritodrine.	Withdrawn
Selegiline	The risk or severity of adverse effects can be increased when Selegiline is combined with Ritodrine.	Approved, Investigational, Vet Approved
Silodosin	Silodosin may decrease the vasoconstricting activities of Ritodrine.	Approved
Sotalol	Sotalol may decrease the bronchodilatory activities of Ritodrine.	Approved
Spironolactone	Spironolactone may decrease the vasoconstricting activities of Ritodrine.	Approved
Synephrine	The risk or severity of adverse effects can be increased when Ritodrine is combined with Synephrine.	Experimental
Tamsulosin	Tamsulosin may decrease the vasoconstricting activities of Ritodrine.	Approved, Investigational
Tedizolid Phosphate	Tedizolid Phosphate may increase the hypertensive activities of Ritodrine.	Approved
Terazosin	Terazosin may decrease the vasoconstricting activities of Ritodrine.	Approved
Terbutaline	The risk or severity of adverse effects can be increased when Ritodrine is combined with Terbutaline.	Approved
Tetryzoline	The risk or severity of adverse effects can be increased when Ritodrine is combined with Tetryzoline.	Approved
Tianeptine	The risk or severity of adverse effects can be increased when Tianeptine is combined with Ritodrine.	Approved
Timolol	Timolol may decrease the bronchodilatory activities of Ritodrine.	Approved
Toloxatone	The risk or severity of adverse effects can be increased when Toloxatone is combined with Ritodrine.	Approved
Torasemide	Ritodrine may increase the hypokalemic activities of Torasemide.	Approved
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Ritodrine.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ritodrine.	Approved
Trichlormethiazide	Ritodrine may increase the hypokalemic activities of Trichlormethiazide.	Approved, Vet Approved
Trimazosin	Trimazosin may decrease the vasoconstricting activities of Ritodrine.	Experimental
Trimipramine	The risk or severity of adverse effects can be increased when Trimipramine is combined with Ritodrine.	Approved
Tyramine	The risk or severity of adverse effects can be increased when Ritodrine is combined with Tyramine.	Investigational, Nutraceutical
Venlafaxine	Venlafaxine may increase the tachycardic activities of Ritodrine.	Approved

Food Interactions

Not Available

References

Synthesis Reference

Naoki Yamazaki, Yoshimasa Fukuda, Yoshiaki Shibazaki, Tetsutarou Niizato, Isao Kosugi, Shin Yoshioka, "(-)-ritodrine, therapeutic compositions and use, and method of preparation." U.S. Patent US5449694, issued July, 1992.

US5449694

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB15005
KEGG Drug	D02359
KEGG Compound	C07239
PubChem Compound	33572
PubChem Substance	46505273
ChemSpider	30971
BindingDB	97162
ChEBI	8872
ChEMBL	CHEMBL785
Therapeutic Targets Database	DAP000937
PharmGKB	PA451258
Drug Product Database	20347
Drugs.com	http://www.drugs.com/cons/ritodrine-oral-intravenous.html
Wikipedia	Ritodrine

ATC Codes

G02CA01 — Ritodrine

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Download (48 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Treatment	Healthy Volunteers	1
4	Completed	Prevention	Premature Births	1
Not Available	Recruiting	Treatment	Premature Labour	1

Pharmacoeconomics

Manufacturers

Abraxis pharmaceutical products
Hospira inc
Astrazeneca lp

Packagers

Solvay Pharmaceuticals

Dosage forms

Form	Route	Strength
Liquid	Intravenous	10 mg
Tablet	Oral	10 mg

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	88-90 °C	Not Available
water solubility	Complete	Not Available
logP	2.4	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.179 mg/mL	ALOGPS
logP	1.53	ALOGPS
logP	1.82	ChemAxon
logS	-3.2	ALOGPS
pKa (Strongest Acidic)	9.15	ChemAxon
pKa (Strongest Basic)	9.81	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	4	ChemAxon
Polar Surface Area	72.72 Å²	ChemAxon
Rotatable Bond Count	6	ChemAxon
Refractivity	83.02 m³·mol^-1	ChemAxon
Polarizability	31.56 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9871
Blood Brain Barrier	-	0.8115
Caco-2 permeable	-	0.5546
P-glycoprotein substrate	Substrate	0.692
P-glycoprotein inhibitor I	Non-inhibitor	0.953
P-glycoprotein inhibitor II	Non-inhibitor	0.8732
Renal organic cation transporter	Non-inhibitor	0.6134
CYP450 2C9 substrate	Non-substrate	0.6367
CYP450 2D6 substrate	Substrate	0.5054
CYP450 3A4 substrate	Non-substrate	0.5874
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.9442
CYP450 2D6 inhibitor	Non-inhibitor	0.6034
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Non-inhibitor	0.8351
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.7277
Ames test	Non AMES toxic	0.7799
Carcinogenicity	Non-carcinogens	0.9177
Biodegradation	Not ready biodegradable	0.8862
Rat acute toxicity	2.2303 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.7534
hERG inhibition (predictor II)	Inhibitor	0.5409

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as phenethylamines. These are compounds containing a phenethylamine moiety, which consists of a phenyl group substituted at the second position by an ethan-1-amine.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Phenethylamines

Direct Parent

Phenethylamines

Alternative Parents

Phenylpropanes / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols

Substituents

Phenethylamine / Phenylpropane / Phenol / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Secondary alcohol / 1,2-aminoalcohol / Secondary amine / Secondary aliphatic amine / Amine

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

amphetamines (CHEBI:8872 )

Targets

Details

1. Beta-2 adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Protein homodimerization activity
Specific Function:: Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:: ADRB2
Uniprot ID:: P07550
Uniprot Name:: Beta-2 adrenergic receptor
Molecular Weight:: 46458.32 Da

References

Tanaka N, Tamai T, Mukaiyama H, Hirabayashi A, Muranaka H, Akahane S, Miyata H, Akahane M: Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence. J Med Chem. 2001 Apr 26;44(9):1436-45. [PubMed:11311067 ]
Schwarz MK, Page P: Preterm labour: an overview of current and emerging therapeutics. Curr Med Chem. 2003 Aug;10(15):1441-68. [PubMed:12871140 ]
Lye SJ, Dayes BA, Freitag CL, Brooks J, Casper RF: Failure of ritodrine to prevent preterm labor in the sheep. Am J Obstet Gynecol. 1992 Nov;167(5):1399-408. [PubMed:1332478 ]
Bianchetti A, Manara L: In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon. Br J Pharmacol. 1990 Aug;100(4):831-9. [PubMed:1976401 ]
Lenselink DR, Kuhlmann RS, Lawrence JM, Kolesari GL: Cardiovascular teratogenicity of terbutaline and ritodrine in the chick embryo. Am J Obstet Gynecol. 1994 Aug;171(2):501-6. [PubMed:8059831 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Details

1. 6-phosphogluconate dehydrogenase, decarboxylating

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Phosphogluconate dehydrogenase (decarboxylating) activity
Specific Function:: Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
Gene Name:: PGD
Uniprot ID:: P52209
Uniprot Name:: 6-phosphogluconate dehydrogenase, decarboxylating
Molecular Weight:: 53139.56 Da

References

Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Aug;25(4):476-9. doi: 10.3109/14756360903257900. [PubMed:20235752 ]
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2017 16:28

Structure for DB00867 (Ritodrine)

Targets

References

Enzymes

References